PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GKOS vs. TMDX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GKOS and TMDX is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

GKOS vs. TMDX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Glaukos Corporation (GKOS) and TransMedics Group, Inc. (TMDX). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%SeptemberOctoberNovemberDecember2025February
-5.27%
-59.04%
GKOS
TMDX

Key characteristics

Sharpe Ratio

GKOS:

0.96

TMDX:

-0.26

Sortino Ratio

GKOS:

1.42

TMDX:

0.11

Omega Ratio

GKOS:

1.21

TMDX:

1.01

Calmar Ratio

GKOS:

1.67

TMDX:

-0.28

Martin Ratio

GKOS:

8.85

TMDX:

-0.55

Ulcer Index

GKOS:

4.14%

TMDX:

34.34%

Daily Std Dev

GKOS:

38.36%

TMDX:

71.68%

Max Drawdown

GKOS:

-69.57%

TMDX:

-73.69%

Current Drawdown

GKOS:

-21.92%

TMDX:

-59.14%

Fundamentals

Market Cap

GKOS:

$7.11B

TMDX:

$2.41B

EPS

GKOS:

-$2.77

TMDX:

$0.93

Total Revenue (TTM)

GKOS:

$277.98M

TMDX:

$319.92M

Gross Profit (TTM)

GKOS:

$212.59M

TMDX:

$189.87M

EBITDA (TTM)

GKOS:

-$67.57M

TMDX:

$46.97M

Returns By Period

In the year-to-date period, GKOS achieves a -16.05% return, which is significantly lower than TMDX's 15.40% return.


GKOS

YTD

-16.05%

1M

-21.38%

6M

-5.28%

1Y

37.63%

5Y*

14.53%

10Y*

N/A

TMDX

YTD

15.40%

1M

16.10%

6M

-59.04%

1Y

-15.16%

5Y*

31.28%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GKOS vs. TMDX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GKOS
The Risk-Adjusted Performance Rank of GKOS is 7979
Overall Rank
The Sharpe Ratio Rank of GKOS is 7777
Sharpe Ratio Rank
The Sortino Ratio Rank of GKOS is 6969
Sortino Ratio Rank
The Omega Ratio Rank of GKOS is 7272
Omega Ratio Rank
The Calmar Ratio Rank of GKOS is 8888
Calmar Ratio Rank
The Martin Ratio Rank of GKOS is 9090
Martin Ratio Rank

TMDX
The Risk-Adjusted Performance Rank of TMDX is 3434
Overall Rank
The Sharpe Ratio Rank of TMDX is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of TMDX is 3535
Sortino Ratio Rank
The Omega Ratio Rank of TMDX is 3535
Omega Ratio Rank
The Calmar Ratio Rank of TMDX is 3030
Calmar Ratio Rank
The Martin Ratio Rank of TMDX is 3636
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GKOS vs. TMDX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Glaukos Corporation (GKOS) and TransMedics Group, Inc. (TMDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GKOS, currently valued at 0.96, compared to the broader market-2.000.002.000.96-0.26
The chart of Sortino ratio for GKOS, currently valued at 1.42, compared to the broader market-4.00-2.000.002.004.006.001.420.11
The chart of Omega ratio for GKOS, currently valued at 1.21, compared to the broader market0.501.001.502.001.211.01
The chart of Calmar ratio for GKOS, currently valued at 1.67, compared to the broader market0.002.004.006.001.67-0.28
The chart of Martin ratio for GKOS, currently valued at 8.85, compared to the broader market-10.000.0010.0020.0030.008.85-0.55
GKOS
TMDX

The current GKOS Sharpe Ratio is 0.96, which is higher than the TMDX Sharpe Ratio of -0.26. The chart below compares the historical Sharpe Ratios of GKOS and TMDX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.00SeptemberOctoberNovemberDecember2025February
0.96
-0.26
GKOS
TMDX

Dividends

GKOS vs. TMDX - Dividend Comparison

Neither GKOS nor TMDX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

GKOS vs. TMDX - Drawdown Comparison

The maximum GKOS drawdown since its inception was -69.57%, smaller than the maximum TMDX drawdown of -73.69%. Use the drawdown chart below to compare losses from any high point for GKOS and TMDX. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-21.92%
-59.14%
GKOS
TMDX

Volatility

GKOS vs. TMDX - Volatility Comparison

Glaukos Corporation (GKOS) has a higher volatility of 24.15% compared to TransMedics Group, Inc. (TMDX) at 16.67%. This indicates that GKOS's price experiences larger fluctuations and is considered to be riskier than TMDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%35.00%40.00%SeptemberOctoberNovemberDecember2025February
24.15%
16.67%
GKOS
TMDX

Financials

GKOS vs. TMDX - Financials Comparison

This section allows you to compare key financial metrics between Glaukos Corporation and TransMedics Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab